Psychotherapy and Pharmacotherapy in Dissociative Disorders
Recruitment status was Active, not recruiting
The purpose of this observational study is to measure the efficacy of a specific combined treatment (psychotherapy and pharmacotherapy) on patients with dissociative disorders, in terms of patients with a favorable outcome by means of the Dissociative Experiences Scale (DES).
Drug: Pharmacological treatment (Quetiapine and/or Escitalopram)
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Interest of a Specific Combined Treatment (Psychotherapy and Pharmacotherapy) in Patients With Dissociative Disorders|
- To study the efficacy of a specific combined treatment (psychotherapy and pharmacotherapy) on patients with dissociative disorders, in terms of patients with a favorable outcome by means of the DES scale. [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
- The relationship between serum lipid levels and depressive symptoms in patients with dissociative disorder during combined treatment. [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||July 2009|
|Primary Completion Date:||April 2009 (Final data collection date for primary outcome measure)|
Combined psychotherapy and pharmacological treatment
Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.
Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered.
Specific psychotherapy for dissociative disorders
Other Name: Dissociative DisordersDrug: Pharmacological treatment (Quetiapine and/or Escitalopram)
Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
Show Detailed Description